After BTIG and JMP Securities gave Sarepta Therapeutics (NASDAQ: SRPT) a Buy rating last month, the company received another Buy, this time from H.C. Wainwright. Analyst Debjit Chattopadhyay maintained a Buy rating on Sarepta Therapeutics today and set a price target of $267. The company’s shares closed on Friday at $122.26.
Chattopadhyay noted:
“Our $267 price target is derived from a risk-adjusted (does not include CMT or Sanfilippo A) DCF analysis and is based on: beta of 1.62, terminal growth rate of 0.5%, risk premium of 4.93%, calculated WACC of 8.4%, and tax rate of 15% beginning in FY 2024.”
According to TipRanks.com, Chattopadhyay is a 3-star analyst with an average return of 1.0% and a 46.2% success rate. Chattopadhyay covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Voyager Therapeutics Inc, and Mersana Therapeutics Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Sarepta Therapeutics with a $208.19 average price target, which is a 70.3% upside from current levels. In a report issued on March 11, Credit Suisse also maintained a Buy rating on the stock with a $207 price target.
See today’s analyst top recommended stocks >>
Based on Sarepta Therapeutics’ latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $141 million. In comparison, last year the company had a GAAP net loss of $24 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.
